Physical Activity and Cerebral Metabolism in the Elderly: a Randomised Controlled Trial
NCT02343029, Not applicable, Completed, Professor Johannes Pantel
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Physical Activity and Cerebral Metabolism in the Elderly: a Randomised Controlled Trial | ClinicalTrials.gov |
| NCT number | NCT02343029 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Professor Johannes Pantel | ClinicalTrials.gov |
| Conditions | Dementia, Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Individualised aerobic exercise training, Waiting Control | ClinicalTrials.gov |
| First posted | 2015-01-21 | ClinicalTrials.gov |
| Last updated | 2015-09-02 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in cerebral metabolism (assessed by MRSI) | 6 month | assessed by MRSI, Primary hypothesis is that aerobic exercise leads to an increase of cerebral N-acetyl-aspartate (NAA; mediated by plasma neurotrophins). Secondary hypothesis stipulates an increase of markers of neuronal energy reserve: i.e. the ratio of phosphocreatinin to creatinine and of adenosine-tri-phosphate (ATP) to \~di-phosphate (ADP). Third hypothesis is an increase in the volume of cortical grey matter | ClinicalTrials.gov |
| Secondary | Cardiopulmonary exercise test (Aerobic exercise capacity is determined by a physician-supervised CPET) | 0, 3 and 6 month | Aerobic exercise capacity is determined by a physician-supervised CPET | ClinicalTrials.gov |
| Secondary | Psychometric testing 1 (verbal declarative memory [Verbal Learning and Memory test; adapted German version of the Rey Auditory Verbal Learning test] | 0, 3 and 6 month | verbal declarative memory \[Verbal Learning and Memory test; adapted German version of the Rey Auditory Verbal Learning test\] | ClinicalTrials.gov |
| Secondary | Psychometric testing 2 (frontal executive control [Colour-Word-Interference test; adapted German version of the Stroop test; Trail-Making-Test Part B] | 0, 3 and 6 month | frontal executive control \[Colour-Word-Interference test; adapted German version of the Stroop test; Trail-Making-Test Part B\] | ClinicalTrials.gov |
| Secondary | Psychometric testing 3 (working memory [Digit Span Test forward and backward] | 0, 3 and 6 month | working memory \[Digit Span Test forward and backward\] | ClinicalTrials.gov |
| Secondary | Psychometric testing 4 9semantic and phonematic fluency, nonverbal declarative memory and visual-constructive abilities by means of the CERAD-Plus (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychological Battery) | 0, 3 and 6 month | semantic and phonematic fluency, nonverbal declarative memory and visual-constructive abilities by means of the CERAD-Plus (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychological Battery | ClinicalTrials.gov |
| Secondary | Psychometric testing 5 (speed of cognitive processing is assessed by means of the Trail-Making-Test Part A) | 0, 3 and 6 month | speed of cognitive processing is assessed by means of the Trail-Making-Test Part A | ClinicalTrials.gov |
| Secondary | Psychometric testing 6 (depressive disorders: Geriatric Depression Scale) | 0, 3 and 6 month | depressive disorders: Geriatric Depression Scale | ClinicalTrials.gov |
| Secondary | Psychometric testing 7 (Age-associated subjective memory impairment is assessed using a memory complaint questionnaire [MAC-Q] | 0, 3 and 6 month | Age-associated subjective memory impairment is assessed using a memory complaint questionnaire \[MAC-Q\] | ClinicalTrials.gov |
| Secondary | Psychometric testing 8 (cristalline intelligence is assessed by means of a verbal intelligence test [Multiple-Choice Word Test: MWT-B] | 0, 3 and 6 month | cristalline intelligence is assessed by means of a verbal intelligence test \[Multiple-Choice Word Test: MWT-B\] | ClinicalTrials.gov |
| Secondary | Psychometric testing 9 (dementia and mild cognitive impairment using the Mini Mental State Examination and the Instrumental Activities of Daily Living Questionnaire) | 0, 3 and 6 month | dementia and mild cognitive impairment using the Mini Mental State Examination and the Instrumental Activities of Daily Living Questionnaire | ClinicalTrials.gov |
| Secondary | Balance and strength (postural sway (balance) and gait data acquisition via the capacitive force-measuring platform (30 Hz) WinFDM v0.0.41® (Zebris© GmbH, Isny, Germany) | 0, 3 and 6 month | postural sway (balance) and gait data acquisition via the capacitive force-measuring platform (30 Hz) WinFDM v0.0.41® (Zebris© GmbH, Isny, Germany) | ClinicalTrials.gov |
| Secondary | Pain Assessment (German Pain Questionnaire) | 0, 3 and 6 month | German Pain Questionnaire | ClinicalTrials.gov |
| Secondary | History of diet (Food frequency questionnaire DEGS1) | 0, 3 and 6 month | Food frequency questionnaire DEGS1 | ClinicalTrials.gov |
| Secondary | History and fear of falling (German version of the Falls-Efficacy-Scale International Version) | 0, 3 and 6 month | German version of the Falls-Efficacy-Scale International Version | ClinicalTrials.gov |
| Secondary | Physical activity (International Physical Activity Questionnaire, Lifetime Total Physical Activity Questionnaire and Accelerometry) | 0, 3 and 6 month | International Physical Activity Questionnaire, Lifetime Total Physical Activity Questionnaire and Accelerometry | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 25872789 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)